Trial of potential Ebola antiviral under way — WHO
GENEVA, Switzerland — The first clinical trial is under way of an antiviral drug's effectiveness in people exposed to the deadly Ebola strain spreading in the Democratic Republic of Congo, the WHO…
Read the full articleYou might also wanna read
Trial of potential Ebola antiviral under way, says WHO
The first clinical trial is under way of an antiviral drug's effectiveness in people exposed to the deadly Ebola strain spreading in the Dem
Congo begins trial of Gilead’s experimental antiviral for Ebola Bundibugyo
July 14 (Reuters) - Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial test
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
The outbreak has led to 1,963 confirmed cases in Congo
Clinical trials begin in DRC epicenter of Bundibugyo strain of Ebola
Clinical trials for treatments targeting the Bundibugyo strain of the Ebola virus disease began on July 2 in the Democratic Republic of Cong
Clinical trials begin in DRC epicenter of Bundibugyo strain of Ebola
Clinical trials for treatments targeting the Bundibugyo strain of the Ebola virus disease began on July 2 in the Democratic Republic of Cong
PARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical tria
who.int·14d agoPARTNERS trial begins enrolling patients in DRC to test treatments for Bundibugyo virus disease
In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical tria
who.int·14d ago
Experimental Ebola treatments begin in Congo as outbreak grows, offering hope to affected residents
Residents in Congo's Ebola outbreak zone are hopeful as researchers begin a study of two potential treatments. The study, launched Thursday
apnews.com·11d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.